Description
Components of the chromatin remodelling switch/sucrose nonfermentable (SWI/SNF) complex are recurrently mutated in tumors, suggesting that altering the activity of the complex plays a role in oncogenesis. BRD9 bromodomain inhibitor is a potent and selective based on a new pyridinone-like scaffold. These compounds modulate BRD9 bromodomain cellular function and display antitumor activity in an AML xenograft model.
